臨床検査52巻11号

2008年10月発行

特集 ホルモンの病態異常と臨床検査 各論Ⅱ　多臓器，組織におけるホルモン相互間作用

3．骨代謝

著者： 吉田守美子¹ 遠藤逸朗¹ 松本俊夫¹

所属機関： ¹徳島大学大学院ヘルスバイオサイエンス研究部生体情報内科学

ページ範囲：P.1330 - P.1336

はじめに

　骨は生体の支柱として姿勢の保持や運動機能に必須であるばかりでなく，内臓や中枢神経系を保護するとともに，内包する造血組織による造血や血中カルシウム・リン濃度の維持に貢献するなど様々な機能を果たしている．また，骨は種々のホルモンの“動的”標的器官として新たな知見が蓄積されつつある．本稿では各種ホルモンが骨代謝に及ぼす影響について，その相互作用や基礎的検討結果，さらに臨床応用も含めて概説するとともに，骨代謝マーカーの測定意義についても述べる．

参考文献

1) Li YC, Amling M, Pirro AE, et al：Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology　139：4391-4396, 1998

2) Horwood NJ, Elliott J, Martin TJ, et al：Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology　139：4743-4746, 1998

3) Paredes R, Arriagada G, Cruzat F, et al：Bone-specific transcription factor Runx2 interacts with the 1alpha, 25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells. Mol Cell Biol　24：8847-8861, 2004

4) The ADHR Consortium：Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet　26：345-348, 2000

5) Shimada T, Mizutani S, Fukumoto S, et al：Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA　98：6500-6505, 2001

6) Jonsson KB, Zahradnik R, Larsson T, et al：Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med　348：1656-1663, 2003

7) Endo I, Fukumoto S, Matsumoto T, et al：Clinical usefulness of measurement of fibroblast growth factor 23(FGF23)in hypophosphatemic patients proposal of diagnostic criteria using FGF23 measurement. Bone　42：1235-1239, 2008

8) Takeuchi Y, Suzuki H, Ogura S, et al：Venous sampling for fibroblast growth factor(FGF)-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab　89：3979-3982, 2004

9) Shimada T, Hasegawa H, Yamazaki Y, et al：FGF23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19：429-435, 2004

10) Urakawa I, Yamazaki Y, Shimada T, et al：Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature　444：774-777, 2006

11) Shimada T, Fukumoto S, Tomizuka K, et al：Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest　113：561-568, 2004

12) Sitara D, Razzaque MS, St-Arnaud R, et al：Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal abnormalities in Fgf-23 null animals. Am J Pathol　169：2161-2170, 2006

13) Hesse M, Fröhlich LF, Zeitz U, et al：Ablation of vitamin D signaling rescues bone, mineral, an glucose homeostasis in Fgf-23 deficient mice. Matrix Biol　26：75-84, 2007

14) Araya K, Fukumoto S, Backenroth R, et al：A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab　90：5523-5527, 2005

15) O'Brien CA, Jia D, Plotkin LI, et al：Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology　145：1835-1841, 2004

16) Van Staa TP, Leufkens HG, Abenhaim L, et al：Use of oral corticosteroids and risk of fractures. J Bone Miner Res　15：993-1000, 2000

17) Nawata H, Soen S, Takayanagi R, et al：Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research(2004). J Bone Miner Metab　23：105-109, 2005

18) Poli V, Balena R, Fattori E, et al：Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J　13：1189-1196, 1994

19) Lorenzo JA, Naprta A, Rao Y, et al：Mice lacking the type I interkeukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology　139：3022-3025, 1998

20) Ammann P, Rizzoli R, Bonjour JP, et al：Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest　99：1699-1703, 1997

21) Cenci S, Weitzmann MN, Gentile MA, et al：M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J Clin Invest　105：1279-1287, 2000

22) Shevde NK, Bendixen AC, Dienger KM, et al：Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA　97：7829-7834, 2000

23) Nakamura T, Imai Y, Matsumoto T, et al：Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell　130：811-823, 2007

24) Smith EP, Boyd J, Frank GR, et al：Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med　331：1056-1061, 1994

25) Erratum in：N Engl J Med 332：131, 1995

26) Bilezikian JP, Morishima A, Bell J, et al：Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med　339：599-603, 1998

27) Kawano H, Sato T, Yamada T, et al：Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA　100：9416-9421, 2003

28) Hillner BE, Ingle JN, Chlebowski RT, et al：American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol　21：4042-4057, 2003

29) Ohlsson C, Bengtsson BA, Isaksson OG, et al：Growth hormone and bone. Endocr Rev　19：55-79, 1998

30) Nishiyama K, Sugimoto T, Kaji H, et al：Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Endocrinology　137：35-41, 1996

31) Williams GR, Zavacki AM, Harney JW, et al：Thyroid hormone receptor binds with unique properties to response elements that contain hexamer domains in an inverted palindrome arrangement. Endocrinology　134：1888-1896, 1994

in osteoclast formation. Biochem Biophys Res Commun　291：987-994, 2002

33) Stevens DA, Harvey CB, Scott AJ, et al：Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol Endocrinol　17：1751-1766, 2003

34) Vestergaard P, Mosekilde L：Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid　13：585-593, 2003

35) Takeda S, Elefteriou F, Levasseur R, et al：Leptin regulates bone formation via the sympathetic nervous system. Cell　111：305-317, 2002

36) Elefteriou F, Ahn JD, Takeda S, et al：Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature　434：514-520, 2005

37) Chen K, Li F, Li J, et al：Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med　12：425-432, 2006

38) 骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会：骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン(2004年度版)．Onteoporos Jpn　12：1191-1204, 2004